Olema Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview

Olema Pharmaceuticals

02/05/2025 13:19

Olema Pharmaceuticals Inc OLMA.OQ OLMA.O is expected to show no change in quarterly revenue when it reports  results on May 6 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Olema Pharmaceuticals Inc is for a loss of 51 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $27.00​, above​ its last closing price of $5.29. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.63
-0.64
-0.51
Beat
20.3
Sep. 30 2024
-0.57
-0.58
-0.60
Missed
-3.8
Jun. 30 2024
-0.55
-0.55
-0.54
Beat
2.6​
Mar. 31 2024
-0.55
-0.55
-0.56
Missed
-2.6
​​Dec. 31 2023
-0.48
-0.48
-0.49
Missed
-1.9
Sep. 30 2023
-0.50
-0.51
-0.48
Beat
6.1​
Jun. 30 2023
-0.72
-0.73
-0.49
Beat
32.6
Mar. 31 2023
-0.71
-0.66
-0.70
Missed
-5.5

This summary was machine generated May 2 at 12:19 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)